Huge numbers of VAERS injury reports on this vaccine and now this

"former Wyeth manufacturing manager Mark Livingston has
filed a lawsuit against the company and two employees, saying that in its
drive to get Prevnar to the market, Wyeth cut production corners that violate Food
and Drug Administration (FDA) rules and which could leave the vaccine
vulnerable to problems with quality control"

http://www.immunizationinfo.org/pressroom/newsbriefs_detail.cfv?id=9835

Lawsuit Alleges Irregularities With Vaccine

Wall Street Journal C1
Hensley, Scott ; McKay, Betsy

03/31/2004

Since its introduction to the market in 2000, the pneumococcal vaccine Prevnar has grown in popularity as a protective barrier against the bacteria, which can cause brain infections and even death, yet its maker Wyeth has run into a string of production problems that have left the company unable to meet demand and prompting the Centers for Disease Control and Prevention to recommend delays in children's four-dose immunization schedules so that infants can have at least some protection with two doses. The vaccine takes a year to produce, so any improvement in Wyeth's production abilities is delayed on the market for a year, leading to continued shortages that are expected through the summer of 2004, though the company claims that at that time, the troubles will be over.

In a twist, however, former Wyeth manufacturing manager Mark Livingston has filed a lawsuit against the company and two employees, saying that in its drive to get Prevnar to the market, Wyeth cut production corners that violate Food and Drug Administration (FDA) rules and which could leave the vaccine vulnerable to problems with quality control. Livingston brought up his concerns at an FDA meeting in July 2003, but he said that because he had not heard any development from the agency since that time, he would go ahead with a civil lawsuit to bring more attention to the matter, claiming that Wyeth's actions amount to fraud against its shareholders by not revealing problems with Prevnar production.